HEPATOCELLULAR carcinoma (HCC) is the fifth most common cancer worldwide in men (1) and the fourth leading cause of cancer death in the United States (2) . Surgical resection or liver transplantation are the only curative treatment options for HCC, but most patients with HCC are not surgical candidates and therefore receive palliative therapies such as radiofrequency ablation or embolization procedures such as bland transcatheter arterial embolization, transcatheter arterial chemoembolization (TACE), or radioembolization (3) (4) (5) . Yttrium-90 radioembolization delivers internal radiation to lesions via catheter-directed intraarterial administration of 90 Y microspheres (5) . Compared with conventional external-beam radiation therapy, selective injection of 90 Y microspheres into HCC lesions increases the regional radiation dose(s) to the lesion areas with low levels of toxicity to the normal liver.
Patients with HCC treated with 90 Y therapy may be candidates for repeated 90 Y administration and/or additional chemoembolization therapies, but the detection of maximum tumor response with use of conventional contrast agent-enhanced magnetic resonance (MR) imaging and/or computed tomography (CT) requires waiting as long as 3 months after therapy (6) . Therefore, early noninvasive imaging biomarkers for predicting maximum response to 90 Y therapy could greatly benefit patients with HCC. Tumor size changes are the traditional criteria used in the noninvasive assessment of HCC response, but the findings may not correlate with therapeutic efficacy (7) . In addition, contrast enhancement after therapy within regions of hemorrhage and edema peripheral to a treated lesion can complicate measurements of tumor size (8) .
Water-mobility measurements with use of diffusion-weighted (DW) MR imaging can be useful for noninvasive interrogation of microstructural tissue properties. Recent studies (9, 10) have demonstrated that quantitative DW MR imaging may provide sensitive clinical biomarkers for early prediction of radiation and chemotherapy response. In these studies (9,10), increased tumor tissue water mobility after therapy was presumed to correspond to decreased cellularity, cell size changes (ie, shrinkage), and compromised cell membrane integrity. Additional studies have recently validated the use of DW MR imaging for differentiation of viable from necrotic tumor tissues in the VX2 rabbit model (11) , and clinical HCC studies (12, 13) have correlated quantitative diffusion measurements with tumor necrosis fraction after TACE. The specific cell death pathways induced by TACE and 90 Y radioembolization therapies are complex and as yet poorly understood. The former combines localized delivery of chemotherapy followed by hypoxia-inducing embolic materials, whereas the later delivers local radiation with little embolic effect. On the basis of previous studies evaluating cell death processes during chemotherapy and radiation therapies (14 -16) , it is expected that TACE and 90 Y radioembolization induce cell death through alternative pathways. Nonetheless, independently of the specific therapy and subsequent therapy-induced cell death pathway (eg, apoptosis, necrosis, senescence, and/or mitotic catastrophe [14, 15, 17] ), tumor tissue destruction should be preceded by microstructural cell morphology changes and therefore changes in local water mobility. Water mobility changes were predictive of response after radiation/chemotherapy in brain tumors (9) and after chemotherapy in metastatic breast tumors (10) . Increases in water mobility after TACE have recently been demonstrated in HCC (13) . However, to our knowledge, no studies have validated DW MR imaging detection of water mobility changes in HCC after 90 Y radioembolization. The purpose of this study was to test the hypothesis that DW MR imaging can detect increased water diffusion as a result of HCC tissue alteration after 90 Y therapy.
MATERIALS AND METHODS

Patients and 90 Y Radioembolization Technique
In this prospective clinical study, which was approved by our institutional review board, superselective 90 Y radioembolization (TheraSphere; MDS Nordion, Kanata, ON, Canada) was performed in six patients who had a primary diagnosis of HCC. The diagnosis of HCC was established by fineneedle aspiration or core biopsy and/or noninvasively on the basis of ␣-fetoprotein levels and previous imaging findings. Patient demographic data including age, cause of lesion, and Child-Pugh classification are given in the Table. None of the patients were deemed candidates for surgical resection. Detailed procedures for the administration of 90 Y microspheres and patient inclusion/exclusion criteria for these studies have been introduced in a previous report (5) . For each patient, angiography with visceral catheterization was performed to evaluate vascular and tumor anatomy and blood flow dynamics to enable optimal placement of the catheter for selective treatment. Coil embolization was used to correct for any risk of gastrointestinal flow. A technetium 99 macroaggregated albumin scan was performed to test for residual gastrointestinal flow and to estimate the percentage of injected activity shunted to the lungs. CT or MR imaging was used to determine the liver volume to which 90 Y microspheres would be delivered. The required activity to be injected and dose received by the liver and lungs were calculated according to previously reported methods (5). TheraSpheres (dose range, 68 -189 Gy) were delivered to the liver tumor via an intraarterial catheter placed in a lobar or segmental branch of the hepatic artery.
MR Imaging Technique
For each patient, anatomic and DW MR imaging were performed before and after 90 Y therapy. The follow-up intervals for each patient are given in the Table. All imaging was performed with a Magnetom Sonata 1.5-T clinical MR scanner (Siemens Medical Solutions, Erlangen, Germany) and a flexible six-channel phased-array abdominal imaging coil. The anatomic MR imaging protocol included T2-weighted half-Fourier acquisition single-shot turbo spin-echo and contrast agent-enhanced T1-weighted gradient echo imaging sequences with fat suppression in arterial and venous phases. DW MR imaging was performed with single-shot spin-echo echoplanar imaging during one or more breath-holds with the following scan parameters: repetition time/echo time, 2,500/82 msec; slice thickness/ gap, 8/4 mm; bandwidth, 1.5 kHz/ pixel; partial Fourier factor, 6/8; nonselective fat saturation; twice refocused spin-echo diffusion weighting to reduce eddy current-induced distortion with b values of 0 and 500 sec/mm 2 .
Image Analysis
An Argus image processing workstation (Siemens) was used for MR imaging processing. Apparent diffusion coefficient (ADC) maps were reconstructed from each series of DW images. With reference to T1-weighted contrast agent-enhanced images, regions of interest were drawn to measure mean tumor ADC values. Tumor signal intensity ratios on T2-weighted and contrast agent-enhanced T1-weighted images were also evaluated. We compared mean tumor ADC values and T1-and T2-weighted tumor signal ratios before and after radioembolization with use of a matched-pair t test with an ␣ value of 0.05.
RESULTS
All the patients in this study were able to complete the imaging protocol without complications. A representative contrast agent-enhanced image and corresponding ADC map are shown in Figure 1 . In this example, the periphery of the larger tumor (lower portion of the image) showed regions of low water mobility within the viable periphery (dark outer rim on the ADC map), whereas the core of the tumor showed increased water mobility corresponding to a necrotic region. T2-weighted half-Fourier acquisition single-shot turbo spin-echo, contrast agent-enhanced, and diffusionweighted (b ϭ 500 sec/mm 2 ) images before and after treatment of a patient with left-lobe HCC are shown in Figure Figure 2 , the contrast enhancement pattern was very similar before and after 90 Y therapy, whereas the diffusion-weighted images demonstrated significant water mobility changes within the core of the tumor after therapy. Contrast agent-enhanced and diffusion-weighted (b ϭ 500 sec/mm 2 ) images before and after treatment of a patient with diffuse HCC are shown in Tumor responses were evaluated by means of long-term follow-up MR and CT imaging and measurement of hepatic function and tumor markers (5, 6) . In long-term follow-up studies, five of the six patients were determined to show a response to the therapy (ie, Ͼ50% decrease in the product of the longest diameter and length of the perpendicular diameter of the lesion or Ͼ50% increased necrosis as assessed with contrast agent-enhanced CT or MR imaging), whereas one patient was classified as not responsive (6) . Although all patients showed increased water diffusion as a result of HCC tissue alteration after 90 Y therapy, the posttreatment increase in ADC value of the patient who did not show a response was less than in the other patients. For the patient who did not show a response to treatment, tumor ADC increased by 0.33 ϫ 10 -3 mm 2 /sec, whereas tumor ADC increased by 0.84 ϫ 10 -3 Ϯ 0.42 mm 2 /sec in the five patients who showed a response. However, the relatively small sample size in this study does not allow testing for statistical significance.
DISCUSSION
In this preliminary study, we successfully demonstrated that DW MR imaging can detect changes in HCC lesions approximately 42 Ϯ 16 days after 90 Y therapy. All six patients completed the study, and MR imaging studies were performed before and after 90 Y therapy. Changes in water diffusion as measured with tumor ADC values on DW MR imaging were statistically significant (P Ͻ .05), whereas tumor changes established by conventional T1-and T2-weighted MR imaging were not statistically significant.
Intraarterial administration of 90 Y is a promising radiation therapy for unresectable HCC.
90 Y delivers a significant radiation dose to target regions, with low toxicity to normal liver and with minimal side effects (5). Immediate and long-term follow-up are necessary for determination of any additional treatments necessary to improve prognosis. Traditional criteria used to detect maximum tumor response by conventional MR imaging and/or CT may be ineffective until 3 months after therapy (6) . DW MR imaging may provide a surrogate imaging biomarker that noninvasively presages changes in tumor response by means of quantification of tissue water mobility. Our study demonstrated the feasibility of DW MR imaging for the detection of significant increases in HCC tumor ADC values after 90 Y radioembolization. DW MR imaging may also offer the potential to differentiate regions of reactive edema from neighboring tumor tissues after 90 Y radioembolization. These regions are often represented by high signal intensities on contrast agent-enhanced T1-weighted images, complicating conventional size measurements.
The primary limitations of this study were the relatively small sample size and the variation in delay between therapy and follow-up imaging. A larger systematic study correlating the time course of tumor ADC changes with longitudinal solid tumor response metrics (ie, Response Evaluation Criteria In Solid Tumors [18] ) will be necessary to validate DW MR imaging as an early biomarker predictive of HCC response. Another limitation was the lack of histologic confirmation of alteration to tumor cell microstructure after 90 Y therapy. Radiation-induced cell death alters tumor cellularity, cell size, and cell membrane integrity. These tissue alterations should lead to decreased intracellular water content (ie, cell shrinkage), increased exchange rates of water molecules between intra-and extracellular populations, and corresponding increases in water mobility and ADC. Previous studies (9) have shown increases in tumor ADC after positive response to externalbeam radiation therapy. Our study also demonstrated tumor ADC increases after therapy; however, we did not perform pathologic studies to establish alterations that correspond to HCC cell structure. Histologic confirmation can be prohibitively invasive and therefore difficult to obtain during the time course of HCC therapy. However, animal model studies offer the potential to provide such pathologic correlations (11) . In addition, 90 Y radioembolization has recently been shown to allow downstaging of HCC in a subset of patients, permitting transplantation or resection (19) . Future studies in these patients may permit explant pathologic correlation to DW MR imaging water-mobility measurements.
Although the single-shot echoplanar imaging technique is commonly used in clinical DW MR imaging of the abdomen because of its relative insensitivity to bulk motion artifacts, it may be limited by significant image distortion, chemical-shift artifacts, and reduced spatial resolution, particularly when the imaging field of view is extended, as is necessary for abdominal imaging applications. These limitations have significantly complicated routine clinical DW MR imaging of the visceral organs. Multishot DW MR imaging pulse sequences such as linescan DW MR imaging (20) and DW MR imaging with periodically rotated overlapping parallel lines with enhanced reconstruction (21) have been investigated in an effort to improve image quality and spatial resolution, particularly for neuroimaging applications. Continued development of these multishot techniques may permit high-resolution DW MR imaging of the abdomen.
In conclusion, DW MR imaging can detect increased water diffusion caused by HCC tissue alteration after 90 Y therapy. DW MR imaging is a promising technique for the noninvasive assessment of tumor response to radioembolization. Future studies are necessary to correlate the time course of ADC changes with HCC therapy response, and additional technical developments are necessary to improve DW image quality and spatial resolution. 
